Corrigendum to “Cytoplasmic localization of Nrf2 promotes colorectal cancer with more aggressive tumors via upregulation of PSMD4” [Free Radic. Biol. Med. 95 (2016) 121–32](S0891584916001209)(10.1016/j.freeradbiomed.2016.03.014);Cytoplasmic localization of Nrf2 promotes colorectal cancer with more aggressive tumors via upregulation of PSMD4

Free Radical Biology and Medicine

Volumn 95, Issue , 2016, Pages 121-132

  Lin, Po Lin ^a   Chang, Jinghua Tsai ^a   Wu, De Wei ^b   Huang, Chi Chou ^a   Lee, Huei ^b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Colorectal cancer; Cytoplasmic Nrf2; PSMD4

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 7,8 DIHYDRO 2 [4 (TRIFLUOROMETHYL)PHENYL] 5H THIOPYRANO[4,3 D]PYRIMIDIN 4 OL; BETA CATENIN; CARFILZOMIB; HEME OXYGENASE 1; I KAPPA B; NAD(P)H DEHYDROGENASE QUINONE 1; PROTEASOME; PROTEIN KINASE B INHIBITOR; PROTEIN P53; PSMD 4; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; HMOX1 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; NQO1 PROTEIN, HUMAN; PSMD4 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CELL INVASION; CELLULAR DISTRIBUTION; COLORECTAL CANCER; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TUMOR XENOGRAFT; UPREGULATION; ADULT; AGED; ANIMAL; CELL NUCLEUS; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; TUMOR INVASION;

ADULT; AGED; ANIMALS; CELL NUCLEUS; COLORECTAL NEOPLASMS; CYTOPLASM; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEME OXYGENASE-1; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); NEOPLASM INVASIVENESS; NF-E2-RELATED FACTOR 2; PROGNOSIS; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 84962009408     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2017.01.021     Document Type: Erratum

References (50)

1. X.J. Wang, Z. Sun, N.F. Villeneuve, S. Zhang, F. Zhao, Y. Li, W. Chen, X. Yi, W. Zheng, G.T. Wondrak, P.K. Wong, and D.D. Zhang Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2 Carcinogenesis 29 2008 1235 1243
2. N. Wakabayashi, S.L. Slocum, J.J. Skoko, S. Shin, and T.W. Kensler When NRF2 talks, who's listening? Antioxid. Redox Signal. 13 2010 1649 1663
3. L. Baird, and A.T. Dinkova-Kostova The cytoprotective role of the Keap1-Nrf2 pathway Arch. Toxicol. 85 2011 241 272
4. I. Ganan-Gomez, Y. Wei, H. Yang, M.C. Boyano-Adanez, and G. Garcia-Manero Oncogenic functions of the transcription factor Nrf2 Free Radic. Biol. Med. 65 2013 750 764
5. P. Shelton, and A.K. Jaiswal The transcription factor NF-E2-related factor 2 (Nrf2): A protooncogene? Faseb J.: Off. Publ. Fed. Am. Soc. Exp. Biol. 27 2013 414 423
6. L.L. Sawa, and A.H. Konga Nrf2 as a chemopreventive target in colorectal cancer Expert Opin. Ther. Targets 15 2011 281 295
7. M.K. Kwak, and T.W. Kensler Targeting NRF2 signaling for cancer chemoprevention Toxicol. Appl. Pharmacol. 244 2010 66 76
8. R. Venugopal, and A.K. Jaiswal Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene Proc. Natl. Acad. Sci. USA. 93 1996 14960 14965
9. J. Alam, D. Stewart, C. Touchard, S. Boinapally, A.M. Choi, and J.L. Cook Nrf2, a Cap'n'Collar transcription factor, regulates induction of the heme oxygenase-1 gene J. Biol. Chem. 274 1999 26071 26078
10. T. Shibata, S. Saito, A. Kokubu, T. Suzuki, M. Yamamoto, and S. Hirohashi Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway Cancer Res. 70 2010 9095 9105
11. D. Malhotra, E. Portales-Casamar, A. Singh, S. Srivastava, D. Arenillas, C. Happel, C. Shyr, N. Wakabayashi, T.W. Kensler, W.W. Wasserman, and S. Biswal Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis Nucleic Acids Res. 38 2010 5718 5734
12. T. Shibata, T. Ohta, K.I. Tong, A. Kokubu, R. Odogawa, K. Tsuta, H. Asamura, M. Yamamoto, and S. Hirohashi Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy Proc. Natl. Acad. Sci. USA 105 2008 13568 13573
13. T. Shibata, A. Kokubu, M. Gotoh, H. Ojima, T. Ohta, M. Yamamoto, and S. Hirohashi Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer 1368 e1351-1354 Gastroenterology 135 2008 1358 1368
14. N. Ban, Y. Takahashi, T. Takayama, T. Kura, T. Katahira, S. Sakamaki, and Y. Niitsu Transfection of glutathione S-transferase (GST)-pi antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide Cancer Res. 56 1996 3577 3582
15. A. Singh, V. Misra, R.K. Thimmulappa, H. Lee, S. Ames, M.O. Hoque, J.G. Herman, S.B. Baylin, D. Sidransky, E. Gabrielson, M.V. Brock, and S. Biswal Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer PLoS Med. 3 2006 e420
16. S. Homma, Y. Ishii, Y. Morishima, T. Yamadori, Y. Matsuno, N. Haraguchi, N. Kikuchi, H. Satoh, T. Sakamoto, N. Hizawa, K. Itoh, and M. Yamamoto Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 15 2009 3423 3432
17. N. Hanada, T. Takahata, Q. Zhou, X. Ye, R. Sun, J. Itoh, A. Ishiguro, H. Kijima, J. Mimura, K. Itoh, S. Fukuda, and Y. Saijo Methylation of the KEAP1 gene promoter region in human colorectal cancer BMC Cancer 12 2012 66
18. T. Ohta, K. Iijima, M. Miyamoto, I. Nakahara, H. Tanaka, M. Ohtsuji, T. Suzuki, A. Kobayashi, J. Yokota, T. Sakiyama, T. Shibata, M. Yamamoto, and S. Hirohashi Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth Cancer Res. 68 2008 1303 1309
19. R. Yu, C. Chen, Y.Y. Mo, V. Hebbar, E.D. Owuor, T.H. Tan, and A.N. Kong Activation of mitogen-activated protein kinase pathways induces antioxidant response element-mediated gene expression via a Nrf2-dependent mechanism J. Biol. Chem. 275 2000 39907 39913
20. C. Xu, X. Yuan, Z. Pan, G. Shen, J.H. Kim, S. Yu, T.O. Khor, W. Li, J. Ma, and A.N. Kong Mechanism of action of isothiocyanates: The induction of ARE-regulated genes is associated with activation of ERK and JNK and the phosphorylation and nuclear translocation of Nrf2 Mol. Cancer Ther. 5 2006 1918 1926
21. S. Papaiahgari, S.R. Kleeberger, H.Y. Cho, D.V. Kalvakolanu, and S.P. Reddy NADPH oxidase and ERK signaling regulates hyperoxia-induced Nrf2-ARE transcriptional response in pulmonary epithelial cells J. Biol. Chem. 279 2004 42302 42312
22. G. Shen, V. Hebbar, S. Nair, C. Xu, W. Li, W. Lin, Y.S. Keum, J. Han, M.A. Gallo, and A.N. Kong Regulation of Nrf2 transactivation domain activity. The differential effects of mitogen-activated protein kinase cascades and synergistic stimulatory effect of Raf and CREB-binding protein J. Biol. Chem. 279 2004 23052 23060
23. Y.S. Keum, S. Yu, P.P. Chang, X. Yuan, J.H. Kim, C. Xu, J. Han, A. Agarwal, and A.N. Kong Mechanism of action of sulforaphane: Inhibition of p38 mitogen-activated protein kinase isoforms contributing to the induction of antioxidant response element-mediated heme oxygenase-1 in human hepatoma HepG2 cells Cancer Res. 66 2006 8804 8813
24. R. Yu, S. Mandlekar, W. Lei, W.E. Fahl, T.H. Tan, and A.N. Kong p38 mitogen-activated protein kinase negatively regulates the induction of phase II drug-metabolizing enzymes that detoxify carcinogens J. Biol. Chem. 275 2000 2322 2327
25. M. Salazar, A.I. Rojo, D. Velasco, R.M. de Sagarra, and A. Cuadrado Glycogen synthase kinase-3beta inhibits the xenobiotic and antioxidant cell response by direct phosphorylation and nuclear exclusion of the transcription factor Nrf2 J. Biol. Chem. 281 2006 14841 14851
26. A.K. Jain, and A.K. Jaiswal GSK-3beta acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2 J. Biol. Chem. 282 2007 16502 16510
27. K. Sakamoto, K. Iwasaki, H. Sugiyama, and Y. Tsuji Role of the tumor suppressor PTEN in antioxidant responsive element-mediated transcription and associated histone modifications Mol. Biol. Cell 20 2009 1606 1617
28. G.M. DeNicola, F.A. Karreth, T.J. Humpton, A. Gopinathan, C. Wei, K. Frese, D. Mangal, K.H. Yu, C.J. Yeo, E.S. Calhoun, F. Scrimieri, J.M. Winter, R.H. Hruban, C. Iacobuzio-Donahue, S.E. Kern, I.A. Blair, and D.A. Tuveson Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis Nature 475 2011 106 109
29. M.C. Tung, P.L. Lin, Y.C. Wang, T.Y. He, M.C. Lee, S.D. Yeh, C.Y. Chen, and H. Lee Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2 Oncotarget 6 2015 41692 41705
30. J. Ishizawa, K. Kojima, N. Hail Jr, Y. Tabe, and M. Andreeff Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein Pharmacol. Ther. 153 2015 25 35
31. A. Dickmanns, T. Monecke, and R. Ficner Structural Basis of Targeting the Exportin CRM1 in cancer Cells 4 2015 538 568
32. A. Noske, W. Weichert, S. Niesporek, A. Roske, A.C. Buckendahl, I. Koch, J. Sehouli, M. Dietel, and C. Denkert Expression of the nuclear export protein chromosomal region maintenance/exportin 1/Xpo1 is a prognostic factor in human ovarian cancer Cancer 112 2008 1733 1743
33. K. Weis Importins and exportins: How to get in and out of the nucleus Trends Biochem. Sci. 23 1998 185 189
34. P.J. van der Watt, and V.D. Leaner The nuclear exporter, Crm1, is regulated by NFY and Sp1 in cancer cells and repressed by p53 in response to DNA Damage Biochim. Biophys. Acta 1809 2011 316 326
35. P. Wang, G.H. Liu, K. Wu, J. Qu, B. Huang, X. Zhang, X. Zhou, L. Gerace, and C. Chen Repression of classical nuclear export by S-nitrosylation of CRM1 J. Cell Sci. 122 2009 3772 3779
36. M. Theodore, Y. Kawai, J. Yang, Y. Kleshchenko, S.P. Reddy, F. Villalta, and I.J. Arinze Multiple nuclear localization signals function in the nuclear import of the transcription factor Nrf2 J. Biol. Chem. 283 2008 8984 8994
37. H.H. Wu, Y.W. Cheng, J.T. Chang, T.C. Wu, W.S. Liu, C.Y. Chen, and H. Lee Subcellular localization of apurinic endonuclease 1 promotes lung tumor aggressiveness via NF-kappaB activation Oncogene 29 2010 4330 4340
38. D.W. Wu, C.C. Huang, S.W. Chang, T.H. Chen, and H. Lee Bcl-2 stabilization by paxillin confers 5-fluorouracil resistance in colorectal cancer Cell Death Differ. 22 2015 779 789
39. P.L. Lin, D.W. Wu, C.C. Huang, T.Y. He, M.C. Chou, G.T. Sheu, and H. Lee MicroRNA-21 promotes tumour malignancy via increased nuclear translocation of beta-catenin and predicts poor outcome in APC-mutated but not in APC-wild-type colorectal cancer Carcinogenesis 35 2014 2175 2182
40. C.Q. Li, M.Y. Kim, L.C. Godoy, A. Thiantanawat, L.J. Trudel, and G.N. Wogan Nitric oxide activation of Keap1/Nrf2 signaling in human colon carcinoma cells Proc. Natl. Acad. Sci. USA 106 2009 14547 14551
41. N. Huber, N. Sakai, T. Eismann, T. Shin, S. Kuboki, J. Blanchard, R. Schuster, M.J. Edwards, H.R. Wong, and A.B. Lentsch Age-related decrease in proteasome expression contributes to defective nuclear factor-kappaB activation during hepatic ischemia/reperfusion Hepatology 49 2009 1718 1728
42. E. Sanchez-Tillo, O. de Barrios, L. Siles, M. Cuatrecasas, A. Castells, and A. Postigo beta-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness Proc. Natl. Acad. Sci. USA 108 2011 19204 19209
43. A. Sparks, S. Dayal, J. Das, P. Robertson, S. Menendez, and M.K. Saville The degradation of p53 and its major E3 ligase Mdm2 is differentially dependent on the proteasomal ubiquitin receptor S5a Oncogene 33 2014 4685 4696
44. G.Y. Liou, and P. Storz Reactive oxygen species in cancer Free Radic. Res. 44 2010 479 496
45. P.T. Schumacker Reactive oxygen species in cancer cells: Live by the sword, die by the sword Cancer Cell 10 2006 175 176
46. T.O. Khor, M.T. Huang, A. Prawan, Y. Liu, X. Hao, S. Yu, W.K. Cheung, J.Y. Chan, B.S. Reddy, C.S. Yang, and A.N. Kong Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer Cancer Prev. Res. 1 2008 187 191
47. G. Rachakonda, K.R. Sekhar, D. Jowhar, P.C. Samson, J.P. Wikswo, R.D. Beauchamp, P.K. Datta, and M.L. Freeman Increased cell migration and plasticity in Nrf2-deficient cancer cell lines Oncogene 29 2010 3703 3714
48. A. Arlt, I. Bauer, C. Schafmayer, J. Tepel, S.S. Muerkoster, M. Brosch, C. Roder, H. Kalthoff, J. Hampe, M.P. Moyer, U.R. Folsch, and H. Schafer Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2) Oncogene 28 2009 3983 3996
49. A. Arlt, S. Sebens, S. Krebs, C. Geismann, M. Grossmann, M.L. Kruse, S. Schreiber, and H. Schafer Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity Oncogene 32 2013 4825 4835
50. D.S. Siegel, T. Martin, M. Wang, R. Vij, A.J. Jakubowiak, S. Lonial, S. Trudel, V. Kukreti, N. Bahlis, M. Alsina, A. Chanan-Khan, F. Buadi, F.J. Reu, G. Somlo, J. Zonder, K. Song, A.K. Stewart, E. Stadtmauer, L. Kunkel, S. Wear, A.F. Wong, R.Z. Orlowski, and S. Jagannath A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma Blood 120 2012 2817 2825